INmune Bio (NASDAQ:INMB) Releases Earnings Results, Beats Estimates By $0.04 EPS

INmune Bio (NASDAQ:INMB) released its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is moving toward regulatory filing — the company completed a rapid-assessed PIP, started process‑validation manufacturing runs, signed a supply agreement with Anthony Nolan for umbilical cords, and expects to submit the U.K. MAA in early Q3 as it aims for commercial manufacture in 2027.
• XPro development continues with additional MINDFuL imaging analyses (MRI myelin preservation and structural integrity) and the company is exploring rare‑disease trials and partner options to define late‑stage/regulatory paths.
• Operational spending fell this quarter, with net loss narrowing to approximately $5.4 million (from $9.7M) and R&D down to ~$3.6M (from $7.6M), reflecting lower burn compared with the prior year period.
• Cash and equivalents were approximately $21.4 million at March 31, 2026, which management says funds operations only through Q1 2027, indicating a near‑term need for additional financing or partnerships to support commercialization and late‑stage programs.

INmune Bio Price Performance

INMB remained flat at $1.43 during trading on Friday. The company’s stock had a trading volume of 240,230 shares, compared to its average volume of 249,626. INmune Bio has a 12-month low of $1.09 and a 12-month high of $11.64. The stock has a market cap of $38.01 million, a price-to-earnings ratio of -0.86 and a beta of 1.04. The stock has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $1.53.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on INMB. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jain Global LLC acquired a new position in shares of INmune Bio in the fourth quarter worth about $66,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of INmune Bio by 20.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after buying an additional 8,427 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of INmune Bio by 269.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock worth $88,000 after buying an additional 41,173 shares during the period. Oxford Asset Management LLP acquired a new position in shares of INmune Bio in the second quarter worth about $52,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of INmune Bio by 1,042.7% in the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after buying an additional 66,700 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.